A Phase 3 clinical trial testing the ability of efzofitimod to safely improve lung function and reduce corticosteroid usage in adults with pulmonary sarcoidosis has dosed its first participant. The aTyr Pharma-sponsored study, dubbed EFZO-FIT, will take place at multiple centers in North America, Europe, and Japan.

And just like that, summer has come to an end. Folks try to hold on to it for as long as they can, but everything must change. Personally, I prefer the fall, my favorite time of year, with its cool, clean, crisp air for me to breathe and comfortable sleeping…

“Don’t let the day get away from you!” Growing up, I remember my family members saying this to my brother and me regularly. It means that you shouldn’t let the day pass you by without doing something. That something could be anything, as long as it was constructive. It was…

Cardiac sarcoidosis may occur more frequently among people who are not current or past smokers, a study has found. The study, “Negative association of smoking history with clinically manifest cardiac sarcoidosis: a case-control study,” was published in CJC Open. Cardiac sarcoidosis is an inflammatory disease that occurs when clumps…

The chance of developing sarcoidosis is nearly halved in those with obstructive sleep apnea (OSA), a sleeping disorder wherein breathing slows or stops repeatedly and for short times during sleep, according to a large study involving U.S. veterans. The findings point to OSA as a protective factor for sarcoidosis.

Patients with sarcoidosis of the heart, called cardiac sarcoidosis, with no other organ involved have more advanced symptoms at their first doctor visit than those with prior involvement of organs other than the heart, a study found. With time, they also develop a type of irregular heartbeat called ventricular…

A few days ago, I celebrated the five-year anniversary of the first of my two spontaneous pneumothoraces, a result of pulmonary sarcoidosis. I can’t believe it’s been five years, but I’m happy to celebrate. By all accounts, I’m stable and doing fairly well. About eight months after my…

The Foundation for Sarcoidosis Research (FSR) has awarded pulmonologist Nancy Lin, MD, at National Jewish Health, the FSR Sarcoidosis Research Fellowship for 2022–2024. Her project, “Defining MicroRNA Biomarkers in Sarcoidosis,” has been granted $150,000 over two years to improve the management of people with sarcoidosis through the identification of…

I’m in the middle of training for the TCS New York City Marathon, the largest marathon in the world. I also have pulmonary sarcoidosis. I have written many times about my love of running, which I discovered at the start of the COVID-19 pandemic. My favorite gyms…

Efzofitimod, an experimental treatment for pulmonary sarcoidosis that’s set to begin Phase 3 clinical testing later this year, has been granted fast track designation by the U.S. Food and Drug Administration (FDA). This designation is designed to speed up the development and review of investigational treatments that aim…